BlackRock Inc. grew its position in shares of Chromadex Corp (NASDAQ:CDXC) by 15.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,238,654 shares of the company’s stock after buying an additional 298,126 shares during the quarter. BlackRock Inc. owned 4.02% of Chromadex worth $10,410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CDXC. JPMorgan Chase & Co. raised its holdings in Chromadex by 377.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 44,807 shares of the company’s stock worth $208,000 after purchasing an additional 35,418 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Chromadex by 8.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 91,370 shares of the company’s stock worth $425,000 after purchasing an additional 6,880 shares during the period. Northern Trust Corp raised its holdings in Chromadex by 0.7% in the 2nd quarter. Northern Trust Corp now owns 416,911 shares of the company’s stock worth $1,939,000 after purchasing an additional 3,090 shares during the period. Finally, Tieton Capital Management LLC raised its holdings in Chromadex by 5.1% in the 2nd quarter. Tieton Capital Management LLC now owns 1,322,570 shares of the company’s stock worth $6,150,000 after purchasing an additional 64,680 shares during the period. 18.48% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Chromadex stock opened at $3.33 on Monday. Chromadex Corp has a one year low of $2.79 and a one year high of $4.95. The stock’s fifty day moving average is $3.83 and its 200 day moving average is $4.20. The stock has a market cap of $198.35 million, a P/E ratio of -5.46 and a beta of 1.38. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.11 and a current ratio of 1.55.

Chromadex (NASDAQ:CDXC) last announced its earnings results on Wednesday, August 7th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01). Chromadex had a negative return on equity of 136.15% and a negative net margin of 85.86%. The company had revenue of $11.10 million during the quarter, compared to the consensus estimate of $10.81 million. Analysts predict that Chromadex Corp will post -0.51 EPS for the current year.

A number of equities analysts recently commented on the company. ValuEngine cut Chromadex from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Oppenheimer assumed coverage on Chromadex in a report on Tuesday, October 15th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, Zacks Investment Research raised Chromadex from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Chromadex has a consensus rating of “Buy” and a consensus target price of $6.00.

About Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

See Also: Growth Stocks

Institutional Ownership by Quarter for Chromadex (NASDAQ:CDXC)

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.